IgM-rheumatoid factor, anti-cyclic citrullinated peptide, and anti-citrullinated human fibrinogen antibodies decrease during treatment with the tumor necrosis factor blocker infliximab in patients with rheumatoid arthritis

Journal of Rheumatology

Volumn 35, Issue 3, 2008, Pages 425-428

  Vis, Marijn ^a   Bos, Wouter H ^c   Wolbink, Gertjan ^c   Voskuyl, Alexandre E ^a   Twisk, Jos W R ^a   Van De Stadt, Rob ^c   Hamann, Dörte ^b   Dijkmans, Ben A C ^a   Lems, Willem F ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b SANQUIN RESEARCH   (Netherlands)

^c JAN VAN BREEMEN INSTITUTE   (Netherlands)

Author keywords

Anti cyclic citrullinated peptide; Rheumatoid arthritis; Rheumatoid factor infliximab

Indexed keywords

AUTOANTIBODY; CITRULLINATED HUMAN FIBRINOGEN ANTIBODY; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; IMMUNOGLOBULIN M; INFLIXIMAB; RHEUMATOID FACTOR; UNCLASSIFIED DRUG;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DRUG DOSE INCREASE; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; COHORT STUDIES; FEMALE; FIBRINOGEN; HUMANS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 40649093607     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)